Clinical trial
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
NCT00080262 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00080262 |
|---|---|
| Title | Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) |
| Official title | Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastases |
| Intervention type | Drug |
| Interventions | Ixabepilone |
| Enrollment | 125 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Mar 26, 2004 |
| Last update posted | Jan 30, 2017 |
| Countries | Argentina, Canada, France, Germany, Mexico, Netherlands, Norway, South Africa, Sweden, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: